65 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to their satisfaction would … of shares subject to any lien, after payment of the costs, shall be applied:
first, in or towards satisfaction of so much of the amount due to the Company
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
of a single transferee or no more than four joint transferees;
it is duly stamped or is duly certificated or otherwise shown to the satisfaction … as the depositary may deem reasonably appropriate, subject however, in each case, to satisfaction of the applicable registration requirements
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
to their satisfaction would have caused them to make reference in connection with their opinion to the subject matter of the disagreement, and (2 … , shall be applied:
first, in or towards satisfaction of so much of the amount due to the Company or of the liability or engagement (as the case may
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
of a single transferee or no more than four joint transferees;
it is duly stamped or is duly certificated or otherwise shown to the satisfaction … and conditions as the depositary may deem reasonably appropriate, subject however, in each case, to satisfaction of the applicable registration requirements
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
to demonstrate to the satisfaction of the FDA, EMA and European Commission or comparable foreign regulatory authorities that a product candidate is safe … with the design or implementation of our or our collaborators’ clinical trials;
we or our collaborators may be unable to demonstrate to the satisfaction of the FDA
10-K
EX-10.13
89ilmo2uxr
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
dyf7t7v
28 Feb 24
Annual report
7:33am
10-K
EX-10.12
ug7mb4uis
28 Feb 24
Annual report
7:33am
8-K
EX-4.1
w1plaw758mtg iswu9c
2 Feb 24
Immunocore Prices Upsized Convertible Senior Notes Offering
4:05pm
8-K
EX-99.1
axafp
2 Feb 24
Immunocore Prices Upsized Convertible Senior Notes Offering
4:05pm
8-K
EX-99.1
v8t031e2ke 7791em
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
6-K
EX-99.4
nm32dta ub5c
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
keevphwexwnv7eympbj
30 Sep 22
Prospectus with selling stockholder info
4:15pm
6-K
EX-1.1
p94fmk
9 Sep 22
Cautionary Note Regarding Forward Looking Statements
4:29pm
424B5
1ygcicj 82d1kdk08
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
g3n9ga1u dss
20 Jul 22
Securities Purchase Agreement
4:06pm
6-K
EX-99.1
5f34u59evzwaoa5qno
20 Jul 22
Securities Purchase Agreement
4:06pm
424B7
5oi1vhvn
5 May 22
Prospectus with selling stockholder info
12:00am
F-3ASR
7y4k4bopwi
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
F-3ASR
EX-4.6
lpphpjg
4 Apr 22
Automatic shelf registration (foreign)
4:08pm